Literature DB >> 2963831

Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.

R Pannell1, J Black, V Gurewich.   

Abstract

Tissue plasminogen activator (t-PA) and/or pro-urokinase (pro-UK) induced lysis of standard 125I-fibrin clots suspended in plasma was studied. Doses were kept below the concentration at which a nonspecific effect was seen, i.e., where fibrinogenolysis and major plasminogen consumption were observed. Small amounts of t-PA potentiated clot lysis by pro-UK by attenuating the lag phase characteristic of pro-UK, and causing a much earlier transition to the rapid phase of lysis. Similar promotion of the fibrinolytic effect of pro-UK was obtained when clots were pretreated with UK or with a little plasmin (less than 1% clot lysis). Promotion by plasmin was nullified by a subsequent treatment of the clot with carboxypeptidase B, indicating that the plasmin effect was related to the exposure of carboxy terminal lysine residues on fibrin. These lysine termini, absent in undegraded fibrin, are known to be essential for the high affinity binding of plasminogen to fibrin. In contrast, clot lysis by t-PA was unaffected by plasmin pretreatment and little affected by carboxypeptidase B treatment of the fibrin substrate. Therefore, plasminogen bound to lysine termini on fibrin, although found to be essential for pro-UK, did not appear to serve as a substrate for t-PA. Selective activation of fibrin bound plasminogen has been attributed to the conformational change in Glu-plasminogen that occurs as a result of binding. The present findings suggest that this conformational change occurs when plasminogen is bound to a terminal lysine but not to an internal lysine. Plasminogen bound to the latter site on fibrin was activated by t-PA and therefore is involved in the ternary complex. This initiates lysis of the undegraded clot and exposes the plasminogen binding sites required by pro-UK. By their complementary activation of fibrin bound plasminogen, t-PA followed by pro-UK induces efficient and synergistic fibrinolysis, whereas each is relatively inefficient when used alone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2963831      PMCID: PMC442536          DOI: 10.1172/JCI113394

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  The effect of epsilon-amino caproic acid on the gross conformation of plasminogen and plasmin.

Authors:  B N Violand; J M Sodetz; F J Castellino
Journal:  Arch Biochem Biophys       Date:  1975-09       Impact factor: 4.013

2.  C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen.

Authors:  U Christensen
Journal:  FEBS Lett       Date:  1985-03-11       Impact factor: 4.124

3.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

4.  Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine.

Authors:  S S Husain; V Gurewich; B Lipinski
Journal:  Arch Biochem Biophys       Date:  1983-01       Impact factor: 4.013

5.  Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator.

Authors:  W Nieuwenhuizen; A Vermond; M Voskuilen; D W Traas; J H Verheijen
Journal:  Biochim Biophys Acta       Date:  1983-10-17

6.  Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.

Authors:  V Gurewich; R Pannell; S Louie; P Kelley; R L Suddith; R Greenlee
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.

Authors:  V Gurewich; R Pannell
Journal:  Thromb Haemost       Date:  1987-06-03       Impact factor: 5.249

8.  The AH-site of plasminogen and two C-terminal fragments. A weak lysine-binding site preferring ligands not carrying a free carboxylate function.

Authors:  U Christensen
Journal:  Biochem J       Date:  1984-10-15       Impact factor: 3.857

9.  Beta(Leu121-Lys122) segment of fibrinogen is in a region essential for plasminogen binding by fibrin fragment E.

Authors:  A Váradi; L Patthy
Journal:  Biochemistry       Date:  1984-04-24       Impact factor: 3.162

10.  Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.

Authors:  P C Harpel; T S Chang; E Verderber
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

View more
  16 in total

Review 1.  New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors:  A V Maksimenko; E G Tischenko
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

2.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

Review 3.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

4.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

Authors:  P A Von dem Borne; L Bajzar; J C Meijers; M E Nesheim; B N Bouma
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

5.  Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.

Authors:  Kyung Yul Lee; Dong Ik Kim; Seo Hyun Kim; Seung Ik Lee; Hae Woong Chung; Yong Woon Shim; Seung Min Kim; Ji Hoe Heo
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

6.  Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Authors:  R Pannell; S Li; V Gurewich
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

7.  Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin.

Authors:  P K Anonick; S L Gonias
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

8.  Plasma carboxypeptidases as regulators of the plasminogen system.

Authors:  A Redlitz; A K Tan; D L Eaton; E F Plow
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset.

Authors:  Moon-Ku Han; Sung Hyun Kim; Sang-Bae Ko; Nam-Jong Paik; O-Ki Kwon; Yong-Seok Lee; Chang-Wan Oh; Jae Hyoung Kim; Seong-Ho Park; Hee-Joon Bae
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 10.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.